Related Experiment Video
Updated: May 11, 2026
09:12
A Protein Microarray Assay for Serological Determination of Antigen-specific Antibody Responses Following Clostridium difficile Infection
Published on: June 15, 2018
Protective efficacy induced by recombinant Clostridium difficile toxin fragments
Rosanna Leuzzi1, Janice Spencer, Anthony Buckley
1Novartis Vaccines and Diagnostics SRL, Siena, Italy.
Infection and Immunity
|May 30, 2013
Summary
Vaccinating mice with specific Clostridium difficile toxin fragments generated antibodies that neutralized both TcdA and TcdB toxins. This vaccination strategy protected hamsters against C. difficile infection, minimizing disease severity.
Area of Science:
- Microbiology
- Immunology
- Toxicology
Background:
- Clostridium difficile infection (CDI) is a significant cause of antibiotic-associated diarrhea and colitis.
- Disease severity in CDI is primarily mediated by two potent enterotoxins: TcdA and TcdB.
- Developing effective vaccines against CDI remains a critical unmet medical need.
Purpose of the Study:
- To evaluate recombinant toxin fragments for their ability to elicit neutralizing antibodies against C. difficile toxins.
- To assess the protective efficacy of promising vaccine candidates in a relevant animal model.
Main Methods:
- Immunization of mice with recombinant fragments of TcdA and TcdB.
- Evaluation of induced systemic IgG antibody responses.
- Testing protective efficacy in a hamster model of C. difficile infection.
- Analysis of toxin neutralization and pathological damage.
Main Results:
- Coadministration of TcdA-B1 and TcdB-GT fragments induced potent systemic IgGs capable of neutralizing both TcdA and TcdB.
- Vaccinated hamsters demonstrated significant protection against lethal challenge with two C. difficile strains.
- Despite high luminal toxin levels during infection, vaccinated animals exhibited minimized pathological damage.
Conclusions:
- Systemic vaccination with a combination of TcdA-B1 and TcdB-GT recombinant polypeptides is a promising strategy for CDI prevention.
- This approach elicits neutralizing antibodies that limit disease pathology by targeting key C. difficile toxins.
- Further development could lead to a novel vaccine for Clostridium difficile infection.
Related Concept Videos
01:12Bacterial Toxins
Bacterial toxins are sophisticated virulence factors that enable pathogenic bacteria to interact with, invade, and damage host tissues. These toxins fall broadly into two types: protein exotoxins, which are secreted into the environment and target specific host receptors, and lipopolysaccharide endotoxins, which are structural components of the bacterial outer membrane released primarily during bacterial lysis or membrane shedding. Exotoxins generally act more selectively, binding to cell...
01:28Diphtheria
Diphtheria is an acute, toxin-mediated infectious disease that primarily affects the upper respiratory tract. It is caused by Corynebacterium diphtheriae, a Gram-positive, pleomorphic rod that lacks spore-forming capability and exhibits a characteristic club-shaped morphology under microscopic examination. While C. diphtheriae can asymptomatically colonize mucosal surfaces, clinical disease manifests only when the bacterial strain is lysogenized by a specific β-corynephage. This phage...
01:18Bacterial Gastroenteritis
Bacterial gastroenteritis, characterized by diarrhea, abdominal cramps, and vomiting, is often caused by ingestion of contaminated food or water and is frequently associated with pathogenic Escherichia coli strains. These microbes exploit two principal mechanisms to inflict disease.Shiga toxin–producing E. coli, also referred to as STEC—notably O157:H7—release Shiga toxins that target ribosomes, blocking protein synthesis. The B subunit of the toxin binds the host glycolipid receptor...